Georgia PGT IVF Hospitals: Qualifications, Process, Costs & Selection Tips

AI Reference Summary

Main Content Begins

1. Georgia PGT IVF Hospitals: Direct Answers to Core Questions

The most common question patients ask is: "Which hospitals in Georgia can actually perform PGT IVF?" The answer is: Among the officially licensed reproductive centers recognized by the Georgian Ministry of Health, approximately 4 to 6 have the capability to independently conduct PGT testing. The key criterion is not whether "third-generation" is advertised, but whether the hospital has its own embryology genetics laboratory (or a fixed partnership with a qualified third-party genetic institution).

PGT (Preimplantation Genetic Testing) includes three types: PGT-A (screening for chromosomal numerical abnormalities), PGT-M (testing for monogenic genetic disorders), and PGT-SR (detecting chromosomal structural abnormalities, such as balanced translocations). In Georgia, most hospitals can only perform PGT-A. PGT-M and PGT-SR typically require sending embryo biopsy samples to reference laboratories in Europe (e.g., Spain, Czech Republic), which adds transportation risks and time costs.

2. Differences Between Hospitals: Laboratory Capability is the Key Differentiator

Industry perspective: If you need something other than PGT-A (e.g., PGT-M), even if a hospital claims to offer it, you should ask: "Where are the samples sent for testing? Does the lab have international accreditation (e.g., CAP, ISO)?" According to practitioner observations, since 2020, two hospitals in Georgia have invested in building their own embryo genetic testing laboratories, while other centers still rely on sending samples abroad.

3. Actual Process: Every Step from Consultation to Transfer

The standard PGT IVF process in Georgia is typically divided into the following stages (using an in-house lab as an example):

• Stage 1: Pre-treatment preparation (completed in home country)
  Female: AMH, FSH, LH, antral follicle count, thyroid function, infectious disease screening (Hepatitis B, Hepatitis C, HIV, Syphilis), coagulation function, chromosomal karyotype analysis.
  Male: Semen analysis + sperm morphology, infectious diseases, chromosomal karyotype.
  Genetic counseling for both partners (if there is a family genetic disorder, provide proband report or genetic test report).
• Stage 2: Ovarian stimulation and egg retrieval (approx. 2 weeks)
  Stimulation starts on day 2–3 of menstruation, with an average of 10–12 days of medication. Egg retrieval is performed under intravenous anesthesia; the number of eggs retrieved depends on ovarian response.
• Stage 3: Embryo culture and biopsy (approx. 5–6 days)
  Fertilization occurs on the day of egg retrieval. Blastocysts form by day 5–6. For blastocysts meeting biopsy criteria (typically stage ≥3, inner cell mass grade B or above), laser drilling is used to aspirate 3–5 trophectoderm cells.
• Stage 4: Genetic testing and freezing (approx. 7 days)
  Biopsy samples are sent to the in-house lab for NGS sequencing. All biopsied blastocysts are cryopreserved (vitrification) during this period.
• Stage 5: Transfer decision and endometrial preparation (approx. 2–4 weeks)
  After the test report is available, a genetic counselor interprets the results. A euploid embryo suitable for transfer is selected. The female partner prepares the endometrium using a hormone replacement cycle or natural cycle. The transfer procedure takes about 5 minutes and requires no anesthesia.
• Stage 6: Post-transfer luteal support and pregnancy test (approx. 2 weeks)
  Blood test for β-hCG is done 12–14 days after transfer. If pregnant, luteal support continues until 8–10 weeks of gestation.

Note: The entire cycle from the first visit to Georgia to the completion of transfer requires at least two stays (one for egg retrieval, one for transfer), with an interval of about 1–2 months. If PGT-M or PGT-SR is performed with samples sent abroad, the timeline extends by 2–3 weeks.

4. Timeline: It is Recommended to Allow 3 Months

If the female partner has low ovarian reserve (AMH < 1.0 ng/mL), it may be necessary to first accumulate eggs or embryos, adding an extra 1–2 menstrual cycles.

5. Suitable and Unsuitable Candidates

Scenarios suitable for considering Georgia PGT IVF:

• Carriers of specific monogenic genetic disorders (e.g., thalassemia, spinal muscular atrophy SMA, hemophilia) – need to confirm the hospital can perform PGT-M and the testing timeline is acceptable;
• Carriers of balanced chromosomal translocations or Robertsonian translocations;
• Female age ≥38, with a known significantly increased risk of embryonic aneuploidy;
• Unexplained recurrent miscarriage (≥2) with no abnormalities found in routine investigations;
• Recurrent implantation failure (≥3 transfers of good-quality embryos without implantation) where an embryonic factor is suspected;
• Those aiming for single embryo transfer to reduce the risk of multiple pregnancy and preferring to prioritize chromosomally normal embryos.

The following situations may make PGT unsuitable or require individualized assessment:

• Very poor ovarian response (AMH < 0.4 ng/mL, antral follicles < 3) – may yield too few eggs, making biopsy difficult and potentially leaving no embryos for transfer;
• Both partners have normal chromosomes, no recurrent miscarriage, age < 35 – PGT-A does not improve live birth rates and increases embryo loss and cost;
• Untreated severe uterine anatomical abnormalities (e.g., large fibroids, intrauterine adhesions);
• Uncontrolled endocrine issues such as thyroid dysfunction or hyperprolactinemia.

6. Doctor's Perspective: The Value Boundaries of PGT

In Georgian reproductive centers, doctors generally hold the following view: PGT does not improve the implantation potential of a single embryo; its role is to screen out chromosomally abnormal embryos, thereby reducing the probability of implantation failure and miscarriage. For older women, PGT-A can significantly reduce implantation failure due to aneuploidy; however, for younger women with an adequate number of embryos, the cost-effectiveness is low. Additionally, PGT has limitations in diagnosing mosaicism, with approximately 2%–4% of embryos diagnosed as "abnormal" potentially forming normal fetuses (false positives), or diagnosed as "normal" but actually abnormal (false negatives). Therefore, doctors recommend combining PGT with non-invasive prenatal testing (NIPT) or amniocentesis for prenatal confirmation.

7. Most Easily Overlooked Details

• Biopsy technique differences: Some hospitals use day 3 cleavage-stage biopsy (not recommended, as too few cells can affect embryo development). The standard practice is day 5–6 blastocyst biopsy, taking 5–8 trophectoderm cells. It is advisable to confirm directly with the hospital that they use blastocyst biopsy.
• Embryo freezing protocol: Some centers in Georgia use open freezing carriers (with direct liquid nitrogen contact with embryos). International standards recommend closed carriers to avoid cross-contamination. You can ask the hospital which consumables they use.
• Genetic counseling step: Many patients mistakenly believe that PGT is a one-time solution. In reality, if testing shows an embryo is normal but transfer still fails, maternal factors (immune, uterine receptivity) or paternal imprinting defects need investigation. The PGT report will indicate "euploid" but does not guarantee a smooth subsequent pregnancy.
• Legal and ethical issues: Georgia permits genetic testing of embryos but prohibits sex selection (unless related to sex-linked genetic disorders). Some hospitals may cooperate with patients for sex selection, which is a grey area and could lead to embryo freezing or legal disputes if discovered.

8. Most Common Pitfalls

9. Frequently Asked Questions (Q&A)

Q: How much does PGT IVF cost in Georgia?
A: A basic PGT-A cycle (including stimulation, egg retrieval, blastocyst culture, biopsy, one test, one transfer) costs approximately 100,000–150,000 RMB. If PGT-M or PGT-SR is needed, plus probe costs (PGT-M requires custom probe development, about 30,000–60,000 RMB), the total cost may exceed 180,000 RMB. It is recommended to request a detailed fee schedule and clarify whether "testing fees are charged per embryo."

Q: I have no genetic disorder, but I am 42 years old. Is PGT-A meaningful?
A: Yes, it is meaningful. In a 42-year-old woman, the proportion of chromosomally normal eggs is less than 15%. PGT-A can screen for euploid embryos for transfer, significantly reducing the miscarriage rate. However, note that if the number of follicles is very low, it may not be possible to obtain enough blastocysts for biopsy. Consider alternative options like egg donation.

Q: How can I verify if a Georgian hospital is legitimate?
A: Request the hospital to provide: ① The reproductive center license number issued by the Georgian Ministry of Health; ② International accreditation for the genetics lab (e.g., ISO 15189 or CAP); ③ Qualification certificates for the embryo biopsy doctor (ESHG or AASH certification); ④ Cooperation contracts with third-party testing institutions (if samples are sent abroad, provide the lab name and logistics plan).

Conclusion: Risk Reminder + Next Steps Suggestions

This article is compiled based on publicly available information in the assisted reproduction industry and practitioner experience. It does not constitute medical advice. For individual diagnosis and treatment, please consult a licensed physician.